A Phase III, Multicenter, Randomized, Open Label, Active-Controlled Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Naive to Complement Inhibitor Therapy
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs HSK 39297 (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Registrational; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 04 Feb 2025 New trial record